Antonio D'Alessio/X
Jan 26, 2025, 08:04
Antonio D’Alessio: RACB Study conversion therapy with AtezoBev in initially unresectable HCC
Antonio D’Alessio, Medical Oncologist and PhD student at Imperial College London, posted on X:
“RACB Study: interesting trial design of conversion therapy with AtezoBev in initially unresectable HCC.
However:
- PR 13%, but resection rate 48%
- Any grade AEs 66%
- No standardized definition of unresectable HCC.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 26, 2025, 07:45
Jan 26, 2025, 07:36
Jan 26, 2025, 07:30
Jan 26, 2025, 07:27
Jan 26, 2025, 07:19
Jan 26, 2025, 07:16